Hephaï, a French start-up that is building a digital learning platform based on artificial intelligence, today announced the appointment of Armel Rusak as commercial director. Through this appointment, Hephaï is strengthening its management team to prepare for the CE identification of its device, to collaborate with partner pharmaceutical laboratories, and to prepare it for launch to the general public by the end of 2022.
In this position, Armel Rusak will be in charge of preparing for the general public launch by the end of 2022. He will coordinate the application testing phase with health professionals and be responsible for developing partnerships with pharmaceutical groups.
“We are delighted to welcome Armel Rusak to Hefei as we enter a strategic time for our start-up. Following the success of Jeffy’s Guide, it was important for us to be able to quickly provide free and easy-to-use educational tools to help patients use their inhalers properly and follow their treatment better in the long run, “said Dr. Valerie Trosini-Dessert. Pulmonologist and co-founder of Hefei.
Armel Rusak acknowledges experience in medical devices in France and Europe. He was previously the commercial director of Neurolite, a company specializing in medical devices, where he was in charge of sleeping pills for pulmonologists. From 2013 to 2015, Armel Rusak Ibren was head of business development in France and Europe. He holds a master’s degree in neuroscience from the University of Montpellier and a master’s degree in business administration from the IAE Montpellier.
“I am proud to be part of a booming start-up that works daily with healthcare professionals and partner pharmaceutical groups to help patients with asthma or COPD. My main task will be to prepare for the public launch of our digital platform, which is scheduled for the end of the year, with the aim of offering patients in France a unique tool to make better use of their inhaled therapy, ”added Armel Rusak.
A unique digital tool based on AI for patients with asthma or COPD
The use of inhaled therapy is very common in the management of asthma and COPD. In order to treat them properly, patients therefore need to operate their inhaler devices on a regular basis, but errors in use are often numerous and can have a direct negative impact on drug administration, especially reducing the benefits of treatment. For example, it is estimated that 30 to 40% of COPD patients abuse their inhaler 1.
Also, during low consultation which either does not allow controlled inhaler therapies to be regulated, or does not allow to properly explain the methods of use of inhalers, even in pharmacy, many patients are not aware of the good habits for their use. Inhaler effectively. Therefore an educational approach is needed to explain the steps for proper use of inhalers.
Thanks to the educational application of Hephaï, it is possible to identify the use of treatment as appropriate or not and to establish a corrective procedure and a potential medical alert if necessary.
The application, which can be used free of charge by the patient and is recommended by the prescribed doctor or pharmacist, will be available on Apple and Android by the end of 2022. It is recognized as a Class 1 medical device.
In France, 41 million inhalers prescribed for respiratory diseases are sold each year. Worldwide, 299 million people are affected by asthma and COPD, including 9 million in France. The global inhaler market is expected to exceed $ 47 billion by 2026, an annual growth of 5.38% between 2021-2026.
1. Molimard M, Rahrison C, Lignote S, et al. Chronic Obstructive Pulmonary Disease Excretion and Inhaler Device Handling: 2935 Patient Real Life Evaluation. Eur Respir J 201 – https://pubmed.ncbi.nlm.nih.gov/28182569/
Source and visual: Hephaï